Human/Mouse/Rat TRAF‑2 Antibody

Detection of TRAF-2 by Western Blot

RAR gamma is required for TNF-induced RIP1-dependent apoptosis and necroptosis. a Cell death analysis of HT-29 clones cont-shRNA, RAR gamma -shRNA-A, RAR gamma -shRNA-B, RAR gamma -shRNA-C or RIP1-shRNA when treated with TSZ for 24 h was determined by PI staining using flow cytometry (left panel) (*P < 0.05 versus cont-shRNA; ANOVA). The bars represent the mean ± s.e.m. of three experiments. Western blot analysis of cells as mentioned in left panel; cell lysates were probed with antibodies as indicated (right panel). b Cell death determination by PI staining using flow cytometry of HT-29 cont-shRNA, RAR gamma -shRNA-A or RAR gamma -shRNA-A cells reconstituted with RAR gamma -shRNA resistant RAR gamma protein (RAR gamma -shRNA-A-rRAR gamma ) when treated with DMSO or TSZ for 24 h (left panel) (*P < 0.05 versus cont-shRNA. #P < 0.05 versus RAR gamma -shRNA-A; ANOVA). The bars represent the mean ± s.e.m. of three experiments. Western blot analysis of cells as mentioned in left panel; cell lysates were probed with antibodies as indicated (right panel). c, d HT-29, RAR gamma -shRNA-A, or RIP1-shRNA cells were treated with necrotic (DMSO, TS, or TSZ) c or apoptotic (CHX, TC or TCZ) d conditions for 24 h. PI positive population was determined by flow cytometry. (*P < 0.05 versus cont-shRNA; ANOVA). The bars represent the mean ± s.e.m. of three experiments. e Western blot analysis of HT-29 cont-shRNA cells infected with TRADD-shRNA, or RAR gamma -shRNA-A cells infected with TRADD-shRNA lentivirus (RAR gamma -shRNA-A + TRADD-shRNA). Cell lysates were probed with antibodies as indicated. f Cells from e were treated with DMSO, TS, or TSZ for 24 h and the PI-positive population was determined by flow cytometry. (*P < 0.05 versus cont-shRNA; ANOVA). The bars represent the mean ± s.e.m. of three experiments. All blots above are representative of one of three experiments Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/28871172), licensed under a CC-BY license. Not internally tested by R&D Systems.

Detection of TRAF-2 by Western Blot

Analysis of the activity of CD40 related proteins involved in transduction leading to activation of key inflammatory/survival pathway and transcription factors. (A, B) Immature dendritic cells were differentiated from monocytes derived from PBMCs donors and treated with the indicated treatments over 4 hours. (A) Representative western blot analysis (n=3-6) of CD40 related signaling adaptor proteins and related inflammatory/survival pathway and transcription factors using beta-actin as a loading control. HERA-CD40L treatment is highlighted by purple rectangles shaded by timepoints. (B) Representative subcellular fractionation and western blot analysis 15 minutes after treatment (n=3), the indicated subcellular fractions are determined by cytosolic, RIPA soluble and insoluble samples, as indicated. RIPA samples correspond to membrane and nuclear fractions while RIPA insoluble samples correspond to insoluble lipid rafts, nuclear insoluble fraction, and bound nuclear chromatin. (C) Dendritic cell activation surface marker expression analysis and IL-12 production comparison between the indicated treatments. Data displayed as mean +/- SEM (n=3 donors), Standard unpaired t-test comparison. Statistics are represented as either not significant (ns), p-value = <0.05 (*), or p-value = <0.005 (***). Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/37304285), licensed under a CC-BY license. Not internally tested by R&D Systems.

Detection of TRAF-2 by Western Blot

Analysis of the activity of CD40 related proteins involved in transduction leading to activation of key inflammatory/survival pathway and transcription factors. (A, B) Immature dendritic cells were differentiated from monocytes derived from PBMCs donors and treated with the indicated treatments over 4 hours. (A) Representative western blot analysis (n=3-6) of CD40 related signaling adaptor proteins and related inflammatory/survival pathway and transcription factors using beta-actin as a loading control. HERA-CD40L treatment is highlighted by purple rectangles shaded by timepoints. (B) Representative subcellular fractionation and western blot analysis 15 minutes after treatment (n=3), the indicated subcellular fractions are determined by cytosolic, RIPA soluble and insoluble samples, as indicated. RIPA samples correspond to membrane and nuclear fractions while RIPA insoluble samples correspond to insoluble lipid rafts, nuclear insoluble fraction, and bound nuclear chromatin. (C) Dendritic cell activation surface marker expression analysis and IL-12 production comparison between the indicated treatments. Data displayed as mean +/- SEM (n=3 donors), Standard unpaired t-test comparison. Statistics are represented as either not significant (ns), p-value = <0.05 (*), or p-value = <0.005 (***). Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/37304285), licensed under a CC-BY license. Not internally tested by R&D Systems.

Detection of TRAF-2 by Western Blot

Analysis of the activity of CD40 related proteins involved in transduction leading to activation of key inflammatory/survival pathway and transcription factors. (A, B) Immature dendritic cells were differentiated from monocytes derived from PBMCs donors and treated with the indicated treatments over 4 hours. (A) Representative western blot analysis (n=3-6) of CD40 related signaling adaptor proteins and related inflammatory/survival pathway and transcription factors using beta-actin as a loading control. HERA-CD40L treatment is highlighted by purple rectangles shaded by timepoints. (B) Representative subcellular fractionation and western blot analysis 15 minutes after treatment (n=3), the indicated subcellular fractions are determined by cytosolic, RIPA soluble and insoluble samples, as indicated. RIPA samples correspond to membrane and nuclear fractions while RIPA insoluble samples correspond to insoluble lipid rafts, nuclear insoluble fraction, and bound nuclear chromatin. (C) Dendritic cell activation surface marker expression analysis and IL-12 production comparison between the indicated treatments. Data displayed as mean +/- SEM (n=3 donors), Standard unpaired t-test comparison. Statistics are represented as either not significant (ns), p-value = <0.05 (*), or p-value = <0.005 (***). Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/37304285), licensed under a CC-BY license. Not internally tested by R&D Systems.

Detection of TRAF-2 by Western Blot

Analysis of the activity of CD40 related proteins involved in transduction leading to activation of key inflammatory/survival pathway and transcription factors. (A, B) Immature dendritic cells were differentiated from monocytes derived from PBMCs donors and treated with the indicated treatments over 4 hours. (A) Representative western blot analysis (n=3-6) of CD40 related signaling adaptor proteins and related inflammatory/survival pathway and transcription factors using beta-actin as a loading control. HERA-CD40L treatment is highlighted by purple rectangles shaded by timepoints. (B) Representative subcellular fractionation and western blot analysis 15 minutes after treatment (n=3), the indicated subcellular fractions are determined by cytosolic, RIPA soluble and insoluble samples, as indicated. RIPA samples correspond to membrane and nuclear fractions while RIPA insoluble samples correspond to insoluble lipid rafts, nuclear insoluble fraction, and bound nuclear chromatin. (C) Dendritic cell activation surface marker expression analysis and IL-12 production comparison between the indicated treatments. Data displayed as mean +/- SEM (n=3 donors), Standard unpaired t-test comparison. Statistics are represented as either not significant (ns), p-value = <0.05 (*), or p-value = <0.005 (***). Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/37304285), licensed under a CC-BY license. Not internally tested by R&D Systems.